Profile data is unavailable for this security.
About the company
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. It is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
- Revenue in USD (TTM)350.00k
- Net income in USD-72.78m
- Incorporated2018
- Employees116.00
- LocationPulse Biosciences Inc3957 Point Eden WayHAYWARD 94545-3720United StatesUSA
- Phone+1 (510) 906-4600
- Fax+1 (302) 655-5049
- Websitehttps://www.pulsebiosciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STAAR Surgical Co | 230.59m | -96.37m | 947.58m | 1.16k | -- | 2.66 | -- | 4.11 | -1.96 | -1.96 | 4.64 | 7.17 | 0.464 | 1.29 | 2.80 | 199,300.80 | -19.39 | 3.81 | -22.26 | 4.42 | 73.87 | 77.03 | -41.79 | 5.42 | 4.35 | -- | 0.00 | 0.00 | -2.64 | 15.89 | -194.66 | -- | 18.11 | -- |
| Butterfly Network Inc | 88.45m | -79.87m | 980.34m | 190.00 | -- | 4.77 | -- | 11.08 | -0.3347 | -0.3347 | 0.3729 | 0.8071 | 0.3186 | 0.7409 | 3.93 | 465,515.80 | -28.77 | -- | -34.57 | -- | 43.24 | -- | -90.31 | -190.03 | 3.56 | -- | 0.00 | -- | 24.52 | -- | 45.78 | -- | -- | -- |
| BioLife Solutions Inc | 96.21m | -12.13m | 1.09bn | 155.00 | -- | 2.92 | -- | 11.31 | -0.2547 | -0.0982 | 2.01 | 7.72 | 0.2389 | 1.15 | 11.24 | 620,735.50 | -3.01 | -1.95 | -3.24 | -2.13 | 64.56 | 54.69 | -12.61 | -9.58 | 4.63 | -- | 0.0133 | -- | 28.89 | 14.88 | -38.08 | -- | 21.40 | -- |
| Pulse Biosciences Inc | 350.00k | -72.78m | 1.28bn | 116.00 | -- | 15.85 | -- | 3,661.70 | -1.08 | -1.08 | 0.0052 | 1.19 | 0.0031 | -- | -- | 3,017.24 | -64.12 | -74.23 | -69.64 | -82.45 | -54.00 | -- | -20,794.57 | -11,780.43 | 10.51 | -- | 0.00 | -- | -- | -- | -35.82 | -- | -5.35 | -- |
| Adapthealth Corp | 3.24bn | -70.27m | 1.31bn | 10.90k | -- | 0.8599 | 3.96 | 0.4038 | -0.5224 | -0.5224 | 23.84 | 11.21 | 0.7372 | 17.60 | 8.33 | 297,693.30 | -1.50 | -1.84 | -1.76 | -2.08 | 21.07 | 20.27 | -2.04 | -2.74 | 0.8109 | 1.96 | 0.5393 | -- | -0.4943 | 25.16 | -185.55 | -- | 57.26 | -- |
| Iradimed Corp | 83.81m | 22.48m | 1.32bn | 160.00 | 59.30 | 13.95 | 78.44 | 15.75 | 1.75 | 1.75 | 6.52 | 7.44 | 0.8094 | -- | -- | -- | 21.71 | 18.06 | 23.86 | 20.21 | 76.75 | 76.85 | 26.82 | 25.51 | -- | -- | -- | -- | 14.43 | 21.45 | 16.88 | 108.61 | -- | -- |
| Kestra Medical Technologies Ltd | 74.26m | -138.79m | 1.33bn | 330.00 | -- | 7.13 | -- | 17.88 | -2.76 | -2.76 | 1.47 | 3.19 | 0.4034 | -- | 9.40 | 225,027.30 | -71.43 | -122.23 | -92.37 | -192.35 | 46.40 | -- | -177.06 | -342.51 | -- | -116.72 | 0.2033 | -- | 115.05 | -- | -25.08 | -- | 150.61 | -- |
| Conmed Corp | 1.37bn | 47.06m | 1.41bn | 3.90k | 30.27 | 1.37 | 11.64 | 1.03 | 1.51 | 1.51 | 44.20 | 33.36 | 0.5936 | 1.78 | 5.66 | 352,493.60 | 2.03 | 2.11 | 2.33 | 2.41 | 54.59 | 54.98 | 3.42 | 3.78 | 1.01 | 3.30 | 0.447 | 51.06 | 5.18 | 9.77 | -64.47 | 37.66 | 8.76 | -5.59 |
| Procept Biorobotics Corp | 308.05m | -95.57m | 1.46bn | 888.00 | -- | 3.99 | -- | 4.74 | -1.72 | -1.72 | 5.55 | 6.50 | 0.5912 | 1.76 | 3.69 | 346,907.70 | -18.34 | -23.13 | -20.70 | -25.70 | 63.70 | 58.76 | -31.02 | -56.52 | 5.77 | -- | 0.1236 | -- | 37.22 | 109.04 | -4.55 | -- | 109.29 | -- |
| Enovis Corp | 2.25bn | -1.18bn | 1.47bn | 7.80k | -- | 0.9868 | -- | 0.6544 | -20.69 | -20.72 | 39.39 | 26.05 | 0.5256 | 1.66 | 5.29 | 288,137.50 | -27.63 | -7.98 | -31.84 | -9.05 | 58.16 | 56.87 | -52.57 | -24.34 | 1.04 | 1.06 | 0.465 | -- | 6.66 | -6.05 | -42.80 | -- | 11.45 | -- |
| Novocure Ltd | 655.35m | -136.23m | 1.54bn | 1.61k | -- | 4.47 | -- | 2.35 | -1.22 | -1.22 | 5.88 | 3.03 | 0.6409 | 4.35 | 8.01 | 408,319.60 | -13.32 | -11.74 | -25.57 | -15.63 | 74.73 | 76.71 | -20.79 | -23.31 | 2.71 | -- | 0.3642 | -- | 8.28 | 5.80 | 19.21 | -- | 12.23 | -- |
| Quidelortho Corp | 2.73bn | -1.13bn | 1.54bn | 6.50k | -- | 0.799 | -- | 0.5636 | -16.66 | -16.66 | 40.25 | 28.28 | 0.4478 | 2.62 | 7.12 | 420,030.80 | -18.56 | -6.45 | -22.13 | -7.39 | 46.67 | 53.89 | -41.45 | -14.40 | 0.9002 | 0.3677 | 0.5798 | -- | -1.89 | 10.44 | 44.84 | -- | 23.72 | -- |
| AtriCure Inc | 534.53m | -11.45m | 1.54bn | 1.35k | -- | 3.13 | 169.62 | 2.88 | -0.241 | -0.241 | 11.19 | 9.88 | 0.8461 | 1.74 | 8.42 | 395,946.70 | -1.81 | -2.67 | -2.07 | -2.98 | 74.98 | 74.88 | -2.14 | -4.13 | 2.99 | -6.75 | 0.1232 | -- | 14.88 | 20.95 | 74.39 | -- | 23.40 | -- |
| UFP Technologies Inc | 602.80m | 68.31m | 1.58bn | 4.15k | 23.28 | 3.72 | 18.02 | 2.61 | 8.78 | 8.78 | 77.44 | 54.96 | 0.9389 | 4.96 | 7.19 | -- | 10.64 | 10.57 | 12.06 | 12.07 | 28.27 | 27.60 | 11.33 | 11.12 | 1.52 | 9.46 | 0.2422 | -- | 19.50 | 27.43 | 15.82 | 38.57 | -- | -- |
| AxoGen Inc | 225.21m | -15.70m | 1.59bn | 622.00 | -- | 11.23 | -- | 7.06 | -0.3413 | -0.3413 | 4.77 | 2.73 | 1.06 | 1.53 | 8.96 | 362,070.80 | -7.38 | -10.17 | -8.46 | -11.70 | 74.31 | 77.27 | -6.97 | -12.34 | 3.31 | -0.9786 | 0.2732 | -- | 20.21 | 14.93 | -57.60 | -- | -24.36 | -- |
Data as of Mar 02 2026. Currency figures normalised to Pulse Biosciences Inc's reporting currency: US Dollar USD
7.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 1.20m | 1.78% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 970.68k | 1.43% |
| Bank of America, NA (Private Banking)as of 31 Dec 2025 | 797.37k | 1.18% |
| Geode Capital Management LLCas of 31 Dec 2025 | 464.61k | 0.69% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 447.07k | 0.66% |
| Portolan Capital Management LLCas of 31 Dec 2025 | 393.50k | 0.58% |
| Griffin Asset Management, Inc.as of 31 Dec 2025 | 226.31k | 0.33% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2025 | 181.59k | 0.27% |
| Charles Schwab Investment Management, Inc.as of 31 Dec 2025 | 152.42k | 0.23% |
| Brooklyn Investment Group LLCas of 31 Dec 2025 | 130.34k | 0.19% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
